Herpikind 200 Tablet DT contains Acyclovir 200 mg, an antiviral agent indicated for the treatment of herpes simplex virus infections, including orolabial and genital herpes, as well as for the management of varicella-zoster virus infections such as shingles and chickenpox. Acyclovir acts by inhibiting viral DNA polymerase, thereby preventing viral DNA synthesis and replication. Herpikind 200 Tablet DT is formulated as a dispersible tablet, facilitating ease of administration and rapid onset of action, particularly beneficial for patients with swallowing difficulties. The medication is typically prescribed to reduce the severity and duration of acute herpes outbreaks and to prevent recurrent episodes in immunocompromised individuals. Dosage and duration of therapy should be individualized based on the type and severity of infection, patient age, and renal function. Common adverse effects may include headache, nausea, diarrhea, and occasional renal impairment, especially in patients with pre-existing kidney conditions. It is contraindicated in patients with known hypersensitivity to acyclovir or valacyclovir. Adequate hydration is recommended during therapy to minimize renal adverse effects. Herpikind 200 Tablet DT should be used under medical supervision, with careful consideration of patient history and concurrent medications to avoid potential drug interactions.